Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Hepatol ; 79(6): 1408-1417, 2023 12.
Article in English | MEDLINE | ID: mdl-37517455

ABSTRACT

BACKGROUND & AIMS: Acute kidney injury (AKI) in cirrhosis is common and associated with high morbidity, but the incidence rates of different etiologies of AKI are not well described in the US. We compared incidence rates, practice patterns, and outcomes across etiologies of AKI in cirrhosis. METHODS: We performed a retrospective cohort study of 11 hospital networks, including consecutive adult patients admitted with AKI and cirrhosis in 2019. The etiology of AKI was adjudicated based on pre-specified clinical definitions (prerenal/hypovolemic AKI, hepatorenal syndrome [HRS-AKI], acute tubular necrosis [ATN], other). RESULTS: A total of 2,063 patients were included (median age 62 [IQR 54-69] years, 38.3% female, median MELD-Na score 26 [19-31]). The most common etiology was prerenal AKI (44.3%), followed by ATN (30.4%) and HRS-AKI (12.1%); 6.0% had other AKI, and 7.2% could not be classified. In our cohort, 8.1% of patients received a liver transplant and 36.5% died by 90 days. The lowest rate of death was observed in patients with prerenal AKI (22.2%; p <0.001), while death rates were higher but not significantly different from each other in those with HRS-AKI and ATN (49.0% vs. 52.7%; p = 0.42). Using prerenal AKI as a reference, the adjusted subdistribution hazard ratio (sHR) for 90-day mortality was higher for HRS-AKI (sHR 2.78; 95% CI 2.18-3.54; p <0.001) and ATN (sHR 2.83; 95% CI 2.36-3.41; p <0.001). In adjusted analysis, higher AKI stage and lack of complete response to treatment were associated with an increased risk of 90-day mortality (p <0.001 for all). CONCLUSION: AKI is a severe complication of cirrhosis. HRS-AKI is uncommon and is associated with similar outcomes to ATN. The etiology of AKI, AKI stage/severity, and non-response to treatment were associated with mortality. Further optimization of vasoconstrictors for HRS-AKI and supportive therapies for ATN are needed. IMPACT AND IMPLICATIONS: Acute kidney injury (AKI) in cirrhosis carries high morbidity, and management is determined by the etiology of injury. However, a large and well-adjudicated multicenter database from US centers that uses updated AKI definitions is lacking. Our findings demonstrate that acute tubular necrosis and hepatorenal syndrome have similar outcomes (∼50% mortality at 90 days), though hepatorenal syndrome is uncommon (12% of all AKI cases). These findings represent practice patterns at US transplant/tertiary centers and can be used as a baseline, presenting the situation prior to the adoption of terlipressin in the US.


Subject(s)
Acute Kidney Injury , Hepatorenal Syndrome , Aged , Female , Humans , Male , Middle Aged , Acute Kidney Injury/epidemiology , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Hepatorenal Syndrome/epidemiology , Hepatorenal Syndrome/etiology , Incidence , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Necrosis/complications , Retrospective Studies
2.
Rejuvenation Res ; 13(5): 561-70, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20645870

ABSTRACT

BACKGROUND: Curcumin, an extract from the rhizome of the plant Curcuma longa (turmeric), has been widely used as a spice and herbal medicine in Asia. It has been suggested to have many biological activities, such as antioxidative, antiinflammatory, anticancer, chemopreventive, and antineurodegenerative properties. We evaluated the impact of curcumin on life span, fecundity, feeding rate, oxidative stress, locomotion, and gene expression in two different wild-type Drosophila melanogaster strains, Canton-S and Ives, under two different experimental conditions. RESULTS: We report that curcumin extended the life span of two different strains of D. melanogaster, an effect that was accompanied by protection against oxidative stress, improvement in locomotion, and chemopreventive effects. Life span extension was gender and genotype specific. Curcumin also modulated the expression of several aging-related genes, including mth, thor, InR, and JNK. CONCLUSIONS: The observed positive effects of curcumin on life span and health span in two different D. melanogaster strains demonstrate a potential applicability of curcumin treatment in mammals. The ability of curcumin to mitigate the expression levels of age-associated genes in young flies suggests that the action of curcumin on these genes is a cause, rather than an effect, of its life span-extending effects.


Subject(s)
Aging/drug effects , Curcumin/pharmacology , Drosophila melanogaster/drug effects , Drosophila melanogaster/genetics , Gene Expression Regulation/drug effects , Health , Longevity/drug effects , Aging/genetics , Animals , Cluster Analysis , Curcumin/administration & dosage , Dietary Supplements , Gene Expression Profiling , Genes, Insect/genetics , Locomotion/drug effects , Longevity/genetics , Oligonucleotide Array Sequence Analysis , Oxidative Stress/drug effects , Protective Agents/administration & dosage , Protective Agents/pharmacology , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis , Transcription, Genetic/drug effects
3.
Drug Discov Today ; 14(15-16): 761-6, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19482095

ABSTRACT

Once a molecule is identified as a potential drug, the detection of adverse drug reactions is one of the key components of its development and the FDA approval process. We propose using Drosophila melanogaster to screen for reproductive adverse drug reactions in the early stages of drug development. Compared with other non-mammalian models, D. melanogaster has many similarities to the mammalian reproductive system, including putative sex hormones and conserved proteins involved in genitourinary development. Furthermore, the D. melanogaster model would present significant advantages in time efficiency and cost-effectiveness compared with mammalian models. We present data on methotrexate (MTX) reproductive adverse events in multiple animal models, including fruit flies, as proof-of-concept for the use of the D. melanogaster model.


Subject(s)
Drug Design , Methotrexate/toxicity , Reproduction/drug effects , Animals , Cost-Benefit Analysis , Drosophila melanogaster/drug effects , Drosophila melanogaster/metabolism , Drosophila melanogaster/physiology , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Male , Models, Animal , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...